2019 Presentations
Thursday, January 31, 2019
The state of cancer care in 2019
Charles Balch
Hematologic Malignancies
The state of cancer care in 2019
Julie Vose
Myelodysplastic Syndromes (MDS): The right treatments for the right patients
Naval Daver
Acute Myelogenous Leukemia (AML): Making sense of the options
Naval Daver
Diffuse Large B-Cell Lymphoma: Is R-CHOP alone enough?
Julie Vose
Multiple Myeloma: Updates and options
Sagar Lonial
Multiple Myeloma: What do we do in early relapse?
Rafael Fonseca
Friday, February 1, 2019
Melanoma/Sarcoma/GU/GI
Melanoma: A new paradigm in adjuvant therapy
Sanjiv Agarwala
Soft Tissue Sarcoma
Shane Morita
RCC Update: Is immunotherapy front-line again?
Ravi Madan
What is the best first-line option for hormone resistant prostate cancer?
Donald Trump
Bladder Cancer: Where does immunotherapy fit in?
Ravi Madan
Updates in GI Cancers
Alan Venook
Lung/HNC
NSCLC: First-line treatment – Immunotherapy, combination chemoimmunotherapy, or targeted therapy?
Julie Brahmer
SCLC: Finally, something new!
Paul Bunn
Immunotherapy in HNSCC: Are we ready for a paradigm shift?
Hyunseok Kang
Saturday, February 2, 2019
Breast Cancer
Updates in the treatment of hormone receptor positive breast cancer in early and late stage disease
Hope S. Rugo
Precision medicine meets breast oncology: Molecular testing to direct treatment decisions
William Gradishar
Optimal therapy for early stage HER2+ breast cancer: A new menu of options
Mark Pegram
Immunotherapy for breast cancer: When, in which patients and what’s next?
Hope S. Rugo
New treatment options for metastatic HER2+ breast cancer
William Gradishar
Key meeting takeaways
Hope S. Rugo